Showing results (181-190 of 207) with videos related to

Sort By:
Pageof 21
Oncotarget|March 15, 2018
The absence of a novel intron 19-retaining <i>ALK</i> transcript (<i>ALK</i>-I19) and <i>MYCN</i> amplification correlates with an excellent clinical outcome in neuroblastoma patientsAbdulraheem Alshareef, Meredith S Irwin, Nidhi Gupta, et al.
Oncotarget|September 12, 2014
Methylation of miR-155-3p in mantle cell lymphoma and other non-Hodgkin's lymphomasRita Lh Yim, Kwan Yeung Wong, Yok Lam Kwong, et al.
Blood|April 30, 2015
STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphomaChengsheng Wu, Ommoleila Molavi, Haifeng Zhang, et al.
Oncotarget|April 15, 2015
Triple negative breast cancers comprise a highly tumorigenic cell subpopulation detectable by its high responsiveness to a Sox2 regulatory region 2 (SRR2) reporterKaren Jung, Nidhi Gupta, Peng Wang, et al.
Antiviral Therapy|August 3, 2007
Factors associated with early hospital discharge of adult influenza patientsNelson Lee, Paul K S Chan, Kin Wing Choi, et al.
Asia-Pacific Journal of Ophthalmology (Philadelphia, Pa.)|April 30, 2020
COVID-19: Special Precautions in Ophthalmic Practice and FAQs on Personal Protection and Mask SelectionDennis S C Lam, Raymond Lai Man Wong, Kenny Ho Wa Lai, et al.
The American Journal of Pathology|September 30, 2005
Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cellsQuan Lin, Raymond Lai, Lucian R Chirieac, et al.
Endocrine-Related Cancer|June 4, 2015
Autotaxin is an inflammatory mediator and therapeutic target in thyroid cancerMatthew G K Benesch, Yi M Ko, Xiaoyun Tang, et al.
Gastroenterology|November 11, 2008
Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancerJames J Farrell, Hany Elsaleh, Miguel Garcia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2007
Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10Pascal Sève, Raymond Lai, Keyue Ding, et al.
Pageof 21